Redeye provides an update following Iconovo’s Q1 2025 report.
Redeye makes slight changes to its Base Case and forecasts following the Q1 report.
The outdoor segment supports strong order bookings Minor estimate revisions '25e EV/EBIT ~7x Outdoo...
Q1 sales lower than expected due to weak end-markets in lightweight Expect positive EBIT margins in ...
Q1: Minor sales miss, but EBIT beat on strong GM We cut our sales estimates slightly, but raise adj.
Redeye comments on Vertiseit’s Q1 reporting, showing solid FX-adjusted ARR growth but somewhat soft ...
Tangiamo Touch Technology (”Tangiamo” eller ”Bolaget”) meddelade den 23 april år 2025 att Bolaget ha...
Redeye provides its initial take on OEM’s Q1 2025 report, which came in slightly below our estimates...
Sales -12%, adj. EBITA -60% vs. cons, -18% org. growth Consensus to lower '25e-'26e EBITA by 3-5% Sh...
Redeye provides a comment following Magle Group’s announcement of the acquisition of Swedish medtech...
Redeye provides a research update following the Q1 report published by Lipum earlier today.
Redeye comments on Powercell’s Q1 report which was mainly in line with our expectations.
Redeye was hoping for a bit more in terms of sales, although market conditions were far from ideal.
Net sales and EBIT were below market consensus (LSEG) in Q1.
Sales -7%, adj. EBIT -2.7m vs. ABGSCe Gross margin at record high level 48% (45%) Performance Chemic...
Q1 sales 3% below our ests. at SEK 207m, for -2.3% org.
Redeye gives its initial take on BONESUPPORT’s Q1 report.
Redeye comments on Fortnox’s Q1, with the key figures matching our expectations.
Redeye comments on Waystream’s Q1 report, which managed to beat our estimates across the board.
Redeye comments on Polygiene Group´s Q1 2025. Polygiene Group delivered positive growth of 18% YoY w...
